CRSP Presents at Goldman Sachs; No New Catalysts, Thesis Unchanged

What happened

CRISPR Therapeutics (CRSP) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, reiterating its focus on Casgevy commercialization and pipeline advancement. The presentation likely highlighted the 75 authorized treatment centers and >500 patients initiating treatment, consistent with recent disclosures. However, the underlying operational bottlenecks—particularly cell collection capacity—remain unresolved, and the company's financial statements still obscure Casgevy's revenue contribution. The stock at ~$53.60 reflects a balance-sheet-supported floor but lacks near-term catalysts to break out. The presentation provided no new data or milestones that would shift the risk-reward profile.

Implication

The Goldman Sachs presentation reaffirmed the existing narrative but did not address the critical gaps: Casgevy revenue transparency, throughput bottlenecks, and dilution risk from ATM/convertibles. Over 6–12 months, returns depend on Casgevy sustaining >$50M quarterly revenue and at least one pipeline catalyst (CTX320 or autoimmunity data). Without these, the stock could drift toward the $45 bear case. Position sizing should account for the $2.44B cash cushion but also the $557M ATM overhang.

Thesis delta

No change. The presentation lacked new operational metrics or financial guidance, leaving the core thesis—Casgevy commercialization scaling and pipeline optionality—intact but unverified. The primary risks (dilution, bottleneck persistence, accounting opacity) remain unchanged, and the bull/bear probabilities are unaltered.